These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12140388)

  • 1. Adjuvant therapy of melanoma: what's new?
    Ascierto PA; Palmieri G; Daponte A; Melucci MT; Satriano RA; Mozzillo N; Castello G;
    Melanoma Res; 2002 Jun; 12(3):293-6. PubMed ID: 12140388
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
    Kirkwood JM; Tarhini AA; Moschos SJ; Panelli MC
    Nat Clin Pract Oncol; 2008 Jan; 5(1):2-3. PubMed ID: 18030300
    [No Abstract]   [Full Text] [Related]  

  • 5. Report on the 4th International Conference on the Adjuvant Therapy of Malignant Melanoma held at the Royal College of Physicians, London, UK, 15-16 March 2002.
    Retsas S; Falkson C; Spitler L
    Melanoma Res; 2002 Jun; 12(3):A1-4. PubMed ID: 12140389
    [No Abstract]   [Full Text] [Related]  

  • 6. Malignant melanoma: non-metastatic.
    Crosby D; Crosby T; Mason M
    Clin Evid; 2002 Jun; (7):1519-29. PubMed ID: 12230768
    [No Abstract]   [Full Text] [Related]  

  • 7. Multidisciplinary treatment of primary melanoma.
    Yao K; Balch G; Winchester DJ
    Surg Clin North Am; 2009 Feb; 89(1):267-81, xi. PubMed ID: 19186240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune phenomena as prognostic markers of response to adjuvant interferon therapy for melanoma.
    Puente Vázquez J; González Larriba JL
    Clin Transl Oncol; 2007 Mar; 9(3):125-6. PubMed ID: 17403622
    [No Abstract]   [Full Text] [Related]  

  • 9. New approaches to the systemic treatment of melanoma.
    Chowdhury S; Vaughan MM; Gore ME
    Cancer Treat Rev; 1999 Oct; 25(5):259-70. PubMed ID: 10544070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha induced Raynaud's syndrome.
    Kruit WH; Eggermont AM; Stoter G
    Ann Oncol; 2000 Nov; 11(11):1501-2. PubMed ID: 11142493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
    Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
    Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-induced obsessive-compulsive symptoms in malignant melanoma.
    Mavrogiorgou P; Juckel G
    Pharmacopsychiatry; 2012 Jan; 45(1):28-30. PubMed ID: 21989604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
    Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
    Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant interferon: extended follow-up times needed?
    Thoren FB; Strannegård Ö
    Lancet Oncol; 2011 May; 12(5):419. PubMed ID: 21536217
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recombinant α-2 interferon in preventing the progression of melanoma].
    Korovin SI; Kukushkina MN; Palivets AIu; Fil'chakov FV; Shumilina ES; Ostafĭchuk VV
    Lik Sprava; 2013 Dec; (8):21-30. PubMed ID: 25726673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What can we learn from phase II adjuvant trials in melanoma?
    Keilholz U; Suciu S; Eggermont AM
    Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
    Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R
    Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.